UNSPSC 51283004: Clindamycin palmitate

This classification denotes a lincosamide antibiotic with the molecular formula C34H63ClN2O6S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C501Z28AFG, chemically known as methyl (2s-trans)-7-chloro-6,7,8-trideoxy-6-(((1-methyl-4-propyl-2-pyrrolidinyl)carbonyl)amino)-1-thio-l-threo-alpha-d-galacto-octopyranoside, monopalmitate (ester) but more generally known as clindamycin palmitate, which bears US NIH Compound Identifier 83855.

Most nations, for tariff and trade purposes, schedule clindamycin palmitate under HS 29419000 and SITC 54139. As of Q4 2014, CLINDAMYCIN PALMITATE remains US FDA's Preferred Term for this commodity. SMILES: CCCCCCCCCCCCCCCC(=O)O[C@@H]1[C@H]([C@H]([C@H](O[C@@H]1SC)[C@@H]([C@H](C)CL)NC(=O)[C@@H]2C[C@H](CN2C)CCC)O)O.

UNSPSC 51283004 Clindamycin palmitate is a Commodity code for a specific antibiotic pharmaceutical product. Recent state and local procurement activity under this code shows little directly relevant solicitation — the two posted opportunities on file are a completed pharmaceutical warehouse piggyback award through Illinois Department of Public Health and a Seminole County, Florida procurement for naloxone and drug deactivation systems, neither of which align with clindamycin palmitate supply. State and local health departments and special districts do procure antibiotics and generic pharmaceuticals through cooperative purchasing consortia (such as MMCAP Infuse), typically via piggyback contracts or volume-based ITB processes, but no active open solicitations for clindamycin palmitate appear in recent activity. When state and local entities do bid pharmaceutical inventory, they bundle multiple drugs in warehouse orders or framework agreements with fixed terms and renewal options spanning 12–36 months, with quarterly or on-demand delivery to central distribution points or facility locations.

The code shows minimal recent concentration. The Illinois Department of Public Health's August 2026 piggyback award to Chartwell Rx LLC under MMCAP Infuse ($2,999,999.11 over three years including renewals) represents the only pharmaceutical warehouse contract in the recent block and involved doxycycline and ciprofloxacin, not clindamycin. Geographic activity is scattered across at least two states (Illinois and Florida), but the Seminole County opportunity falls outside the code's scope entirely. No active solicitation for clindamycin palmitate supply appears to be open at this time; prospecting under this code would require monitoring state and local RFQs and ITBs for pharmaceutical inventory bundled into broader health-system or emergency-medical supply contracts.